PFG Advisors Acquires 49 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

PFG Advisors increased its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 0.8% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,837 shares of the medical equipment provider’s stock after buying an additional 49 shares during the period. PFG Advisors’ holdings in Intuitive Surgical were worth $3,047,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently bought and sold shares of ISRG. Berbice Capital Management LLC bought a new position in Intuitive Surgical in the fourth quarter worth approximately $26,000. BankPlus Trust Department bought a new position in Intuitive Surgical in the fourth quarter worth approximately $28,000. Kohmann Bosshard Financial Services LLC acquired a new position in shares of Intuitive Surgical during the fourth quarter worth $31,000. MidAtlantic Capital Management Inc. acquired a new position in shares of Intuitive Surgical during the third quarter worth $33,000. Finally, Decker Retirement Planning Inc. acquired a new position in shares of Intuitive Surgical during the fourth quarter worth $36,000. Institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Stock Performance

NASDAQ:ISRG opened at $497.30 on Thursday. Intuitive Surgical, Inc. has a one year low of $364.17 and a one year high of $616.00. The firm has a market cap of $177.13 billion, a price-to-earnings ratio of 77.58, a PEG ratio of 5.85 and a beta of 1.43. The firm’s fifty day moving average is $569.42 and its two-hundred day moving average is $531.60.

Insider Buying and Selling at Intuitive Surgical

In other news, EVP Brian Edward Miller sold 8,900 shares of the stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $485.07, for a total transaction of $4,317,123.00. Following the sale, the executive vice president now directly owns 5,758 shares of the company’s stock, valued at $2,793,033.06. This represents a 60.72 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Myriam Curet sold 408 shares of the stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $589.75, for a total transaction of $240,618.00. Following the sale, the executive vice president now directly owns 353 shares in the company, valued at approximately $208,181.75. The trade was a 53.61 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 22,209 shares of company stock valued at $11,928,127. 0.90% of the stock is owned by insiders.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on ISRG shares. BTIG Research upped their price target on Intuitive Surgical from $535.00 to $561.00 and gave the stock a “buy” rating in a research report on Tuesday, November 26th. Truist Financial upped their price target on Intuitive Surgical from $640.00 to $666.00 and gave the stock a “buy” rating in a research report on Friday, January 24th. Piper Sandler reaffirmed an “overweight” rating and set a $670.00 price target (up from $538.00) on shares of Intuitive Surgical in a research report on Friday, January 24th. JPMorgan Chase & Co. upped their price target on Intuitive Surgical from $575.00 to $675.00 and gave the stock an “overweight” rating in a research report on Friday, January 24th. Finally, Evercore ISI upped their price target on Intuitive Surgical from $490.00 to $530.00 in a research report on Monday, January 27th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $613.10.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.